Crizotinib (Xalkori®)

Assessment Status NCPE Assessment process complete
Drug Crizotinib
Brand Xalkori®
Indication Treatment of adults with previously treated anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC) (i.e. in the 2nd / 3rd–line treatment setting)
Assessment Process
Rapid review commissioned 09/01/2013
Rapid review completed 31/01/2013
Rapid review outcome Full Pharmacoeconomic Evaluation Recommended
Full submission received from Applicant 24/05/2013
NCPE assessment completed 27/08/2013
NCPE assessment outcome Reimbursement not recommended. The NCPE do not consider Crizotinib (Xalkori®) a cost-effective treatment for adult patients with previously treated ALK positive advanced non small cell lung cancer (NSCLC).

August 2015

The HSE has approved reimbursement following confidential price negotiations.

Technical Summary